142 related articles for article (PubMed ID: 15876430)
1. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer.
Chang JW; Lee SH; Jeong JY; Chae HZ; Kim YC; Park ZY; Yoo YJ
FEBS Lett; 2005 May; 579(13):2873-7. PubMed ID: 15876430
[TBL] [Abstract][Full Text] [Related]
2. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma.
Fujita Y; Nakanishi T; Hiramatsu M; Mabuchi H; Miyamoto Y; Miyamoto A; Shimizu A; Tanigawa N
Clin Cancer Res; 2006 Nov; 12(21):6415-20. PubMed ID: 17085654
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of secreted proteins of non-small cell lung cancer.
Huang LJ; Chen SX; Luo WJ; Jiang HH; Zhang PF; Yi H
Ai Zheng; 2006 Nov; 25(11):1361-7. PubMed ID: 17094902
[TBL] [Abstract][Full Text] [Related]
4. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung.
Park JH; Kim YS; Lee HL; Shim JY; Lee KS; Oh YJ; Shin SS; Choi YH; Park KJ; Park RW; Hwang SC
Respirology; 2006 May; 11(3):269-75. PubMed ID: 16635084
[TBL] [Abstract][Full Text] [Related]
5. Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer.
Yao X; Jiang H; Zhang C; Wang H; Yang L; Yu Y; Yu J; Shi B; Shen Z; Gao H; Chen Z; Tian S; Lu S; Li Z; Gu J
Biomarkers; 2010 Mar; 15(2):128-34. PubMed ID: 19839718
[TBL] [Abstract][Full Text] [Related]
6. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer.
Huang LJ; Chen SX; Huang Y; Luo WJ; Jiang HH; Hu QH; Zhang PF; Yi H
Lung Cancer; 2006 Oct; 54(1):87-94. PubMed ID: 16876904
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of peroxiredoxin in human breast cancer.
Noh DY; Ahn SJ; Lee RA; Kim SW; Park IA; Chae HZ
Anticancer Res; 2001; 21(3B):2085-90. PubMed ID: 11497302
[TBL] [Abstract][Full Text] [Related]
8. Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors.
Bazhin AV; Savchenko MS; Shifrina ON; Demoura SA; Chikina SY; Jaques G; Kogan EA; Chuchalin AG; Philippov PP
Lung Cancer; 2004 May; 44(2):193-8. PubMed ID: 15084384
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
10. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA).
Hamrita B; Chahed K; Kabbage M; Guillier CL; Trimeche M; Chaïeb A; Chouchane L
Clin Chim Acta; 2008 Jul; 393(2):95-102. PubMed ID: 18424265
[TBL] [Abstract][Full Text] [Related]
11. Anti-survivin antibody responses in lung cancer.
Karanikas V; Khalil S; Kerenidi T; Gourgoulianis KI; Germenis AE
Cancer Lett; 2009 Sep; 282(2):159-66. PubMed ID: 19380192
[TBL] [Abstract][Full Text] [Related]
12. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
13. Augmented expression of peroxiredoxin I in lung cancer.
Chang JW; Jeon HB; Lee JH; Yoo JS; Chun JS; Kim JH; Yoo YJ
Biochem Biophys Res Commun; 2001 Nov; 289(2):507-12. PubMed ID: 11716502
[TBL] [Abstract][Full Text] [Related]
14. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer.
Chen Y; Zhang H; Xu A; Li N; Liu J; Liu C; Lv D; Wu S; Huang L; Yang S; He D; Xiao X
Lung Cancer; 2006 Oct; 54(1):95-102. PubMed ID: 16890323
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of antioxidant proteins in brains of patients with sporadic Creutzfeldt-Jacob disease.
Krapfenbauer K; Yoo BC; Fountoulakis M; Mitrova E; Lubec G
Electrophoresis; 2002 Aug; 23(15):2541-7. PubMed ID: 12210213
[TBL] [Abstract][Full Text] [Related]
16. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment.
Chen MF; Chen WC; Wu CT; Lin PY; Shau H; Liao SK; Yang CT; Lee KD
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1461-72. PubMed ID: 17084559
[TBL] [Abstract][Full Text] [Related]
17. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
Kanoh Y; Ohara T; Mashiko T; Abe T; Masuda N; Akahoshi T
Anticancer Res; 2006; 26(6B):4293-7. PubMed ID: 17201147
[TBL] [Abstract][Full Text] [Related]
18. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
19. X-radiation induces non-small-cell lung cancer apoptosis by upregulation of Axin expression.
Han Y; Wang Y; Xu HT; Yang LH; Wei Q; Liu Y; Zhang Y; Zhao Y; Dai SD; Miao Y; Yu JH; Zhang JY; Li G; Yuan XM; Wang EH
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):518-26. PubMed ID: 19735876
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression.
Chen MF; Keng PC; Shau H; Wu CT; Hu YC; Liao SK; Chen WC
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):581-91. PubMed ID: 16414373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
